US point-of-care testing market faces tough challenges
This article was originally published in Clinica
The point-of-care testing (POCT) market in the US is worth some $1.6 billion and accounts for 25% of the overall diagnostic market.
You may also be interested in...
The funding will be used to support clinical and preclinical development at its portfolio companies, with 8-10 programs in the clinic in 2021.
Health policy changes that President-elect Joe Biden will likely make during his four-year term include Medicaid expansion and a greater reliance on medical science, among others, experts say.
Already cleared to monitor the viral load in HIV-positive individuals, the test has now been approved for initial diagnosis as well.